Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

Holweger, Karin; Lipp, Hans‐Peter; Beijnen, Jos H.; Bokemeyer, Carsten; Hartmann, J. T.

doi:10.1007/s00280-010-1537-0

Cited by 5 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 8 studies that reported mCL Cr, the mean was 81AE21 mL/ min. 15,19,20,22,23,31,32 No studies reported measured GFR. The Cockcroft-Gault formula was the primary serum creatinineebased reference equation studied, and several approaches to estimating GFR from cystatin C (eGFR Cystatin C ) were reported, including the CKD EPI, Flodin, Larsson, Hoek, Macdonald, and Sjostrom equations.…”

Section: Study Identification and Characteristicsmentioning

confidence: 99%

Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review

Barreto

Rule

Murad

et al. 2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (!18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement (%), therapeutic failure (%), and drug toxicity (%). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin Cebased estimated glomerular filtration rate (eGFR Cystatin C ) was more predictive of drug levels and drug clearance than eGFR Creatinine . In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFR Creatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFR Creatinine , use of eGFR Cystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.

show abstract

Section: Study Identification and Characteristicsmentioning

confidence: 99%

Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review

Barreto

Rule

Murad

et al. 2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…The data for the use of serum cystatin C to estimate GFR in patients with stable renal function and consequently drug clearance are somewhat limited but promising. Several renally eliminated medications have been tested including antimicrobial agents, cardiovascular drugs, and chemotherapeutics, but strategies to implement the use of this biomarker routinely at the bedside are lacking . In the case of vancomycin, serum cystatin C or the associated eGFR better predicted vancomycin clearance than creatinine in pharmacokinetic models, especially among those with altered skeletal muscle mass …”

Section: Practical Models Of Biomarker Utilizationmentioning

confidence: 99%

“…Several renally eliminated medications have been tested including antimicrobial agents, cardiovascular drugs, and chemotherapeutics, but strategies to implement the use of this biomarker routinely at the bedside are lacking. [22][23][24][25][26][27][28][29] In the case of vancomycin, serum cystatin C or the associated eGFR better predicted vancomycin clearance than creatinine in pharmacokinetic models, especially among those with altered skeletal muscle mass. [30][31][32][33][34][35] Case Study: Cystatin C for Vancomycin Dosing…”

Section: Practical Models Of Biomarker Utilizationmentioning

confidence: 99%

Innovative Use of Novel Biomarkers to Improve the Safety of Renally Eliminated and Nephrotoxic Medications

et al. 2018

View full text Add to dashboard Cite

Over the last decade, the discovery of novel renal biomarkers and research on their use to improve medication effectiveness and safety has expanded considerably. Pharmacists are uniquely positioned to leverage this new technology for renal assessment to improve medication dosing and monitoring. Serum cystatin C is a relatively new, inexpensive, functional renal biomarker that responds more quickly to changing renal function than creatinine and is not meaningfully affected by age, sex, skeletal muscle mass, dietary intake, or deconditioning. Cystatin C has been proposed as an adjunct or alternative to creatinine for glomerular filtration rate assessment and estimation of drug clearance. Tissue inhibitor of metalloproteinase-2·insulin-like growth factor-binding protein 7 ([TIMP-2]·[IGFBP7]) is a composite of two damage biomarkers released into the urine at a checkpoint in mitosis when renal cells undergo stress or sense a future risk of damage. Concentrations of [TIMP-2]·[IGFBP7] increase before a rise in serum creatinine is evident, thus providing insightful information for evaluation in the context of other patient data to predict the risk for impending kidney injury. This article provides a brief overview of novel renal biomarkers being used as a mechanism to improve medication safety including a discussion of cystatin C, as part of drug-dosing algorithms and specifically for vancomycin dosing, and the use of [TIMP-2]·[IGFBP7] for risk prediction in acute kidney injury and drug-induced kidney disease. Select cases of clinical experience with novel renal biomarkers are outlined, and lessons learned and future applications are described.

show abstract

“…Holweger et al [1] calculated carboplatin administered dose by a modified Calvert formula whereas GFR was substituted by CrCl via 24-h urine collection or calculated by Jelliffe. We don't know how many patients were dosed with 24-h urine collection or with Jelliffe formula in this study.…”

Section: Estimating the Correct Way Of Calculating The Carboplatin Dosementioning

confidence: 99%

“…In this study, that included 290 patients, the best method to estimate GRF was Cockcroft-Gault. In Holweger et al study [1] the Cockcroft-Gault estimation in obese patients was carried out using the actual body weight. It is known that when actual body weight is used, in patients with BMI>30kg/m 2 , it can conduce to overdosification.…”

Section: Estimating the Correct Way Of Calculating The Carboplatin Dosementioning

confidence: 99%

Estimating the correct way of calculating the carboplatin dose

Sierra-Sánchez

González-Carrascosa

2011

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

Cited by 5 publications

References 30 publications

Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review

Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review

Innovative Use of Novel Biomarkers to Improve the Safety of Renally Eliminated and Nephrotoxic Medications

Estimating the correct way of calculating the carboplatin dose

Contact Info

Product

Resources

About